Seasonal Allergic Rhinoconjunctivitis Clinical Trial
Official title:
Preliminary Assessment of the Clinical Tolerability, Safety and Immunogenicity of Three Different Doses of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis
The purpose of this study is to determine whether the oral administration of grass pollen peptides is safe and effective in the treatment of allergic rhinitis.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01111279 -
Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis
|
Phase 1 | |
| Completed |
NCT00813046 -
Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis
|
Phase 1 | |
| Completed |
NCT02761252 -
Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma
|
Phase 4 |